Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-02-28
Target enrollment:
Participant gender:
Summary
This study is a phase 2, multicenter, interventional for cohort 1 & 2, non-interventional for
cohort 3, open-label trial of cabozantinib, with ORR as the primary efficacy endpoint. In
total, 201 eligible subjects will enroll from 5 sites in Korea. The intervention for this
cohort 1&2 is only IMP, Cabometyx provided by Ipsen (off-label). Also, cohort 3 is just RWD
without IMP (on-label)